ALK and non-small cell lung carcinoma: Therefore, ALK fusion proteins are already important clinical targets in non-small cell lung cancer (EMLA4-ALK) but have also been described in diffuse large cell lymphoma (NPM-ALK) and in inflammatory myofibroblastic tumour (TPM3-ALK).